BTIG Maintains Buy on Nektar Therapeutics, Raises Price Target to $178

Benzinga Newsdesk www.benzinga.com Positive 83.0%

Neg 0% Neu 0% Pos 83%

BTIG analyst Julian Harrison maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $151 to $178.